Lupus drug may shield blood vessels from heart attack and stroke

NCT ID NCT05440422

Recruiting now Disease control Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 01, 2026 · Updated 15 times

Summary

This study tests whether the drug anifrolumab can improve blood vessel health and reduce inflammation in people with lupus, who face higher risks of heart attacks and strokes. About 45 adults with lupus will receive either anifrolumab or a placebo through IV infusions over 8 months. Researchers will measure changes in blood vessel stiffness and inflammation using special tests like CAVI and PET scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CARDIOVASCULAR DISEASE PREMATURE ATHEROSCLEROSIS PREMATURE ATHEROSCLEROSIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC LUPUS ERYTHEMATOSUS